Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
Explore this paper's citation graph
Summary
As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
- Type
- article
- Published
- 2017-06-06
- Cited by
- 2,199
- References
- 18
- Access
- Open access
- OpenAlex
- https://openalex.org/W2624310346
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12154034
Keywords
Alectinib, Crizotinib, Medicine, Ceritinib, Lung cancer
References
- ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond
- Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
- NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Cited by
- Pattern of care and survival of anaplastic lymphoma kinase rearranged non–small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis
- Anticipating the Next Step in the Management of ALK-Positive NSCLC.
- Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
- Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy.
- Targeting anaplastic lymphoma kinase in neuroblastoma
- Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema
- 驱动基因阳性肺癌脑转移患者的靶向治疗进展
- Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
- CBNPC avec translocation ALK/ROS
- Molecular profiling of non-small cell lung cancer
- Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
- Targeted therapies: Defining the best-in-class in NSCLC
- The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients
- The J-ALEX trial-is frontline alectinib a new standard of care?
- Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
- A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay.
- Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents
- Treatment of ALK‐rearranged non‐small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
- ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
Related papers
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
- How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
- The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
- Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
- Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
- Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
- Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
- Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
- ALK: a tyrosine kinase target for cancer therapy